ArticlehLife2025
Systemic profiling of immune responses in healthy adults vaccinated with an RBD-targeting COVID-19 mRNA vaccine.
Article in hLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines have succeeded unprecedentedly due to high protection efficacy and robust immune responses. However, systematic and longitudinal profiling of immune responses in mRNA vaccine recipients remains limited. Here, a cohort of ten healthy volunteers who received two doses of ARCoV, a non-modified mRNA vaccine, were enrolled. Peripheral blood samples were collected and analyzed using Olink technology, antibody detection, intracellular cytokine staining, single-cell sequencing, and T cell receptor (TCR) sequencing. ARCoV vaccination induced potent humoral and cellular immune responses, as well as elevated cytokines including C-X-C motif chemokine ligand 10 (CXCL10) and interferon-gamma (IFN-γ). Single-cell sequencing revealed that ARCoV immunization induced an increased relative abundance of interferon-activated T cells, proliferative T cells, and naïve T cells. Monocytes and dendritic cells exhibited activation of the innate immune response, downregulation of hypoxia and glycolysis pathways, and a transient decrease in their proportions. Integrative analysis of single-cell RNA and TCR sequencing identified clonal expansion of effector T cells and killer cell immunoglobulin-like receptor (KIR)-expressing natural killer-like cells after the second dose. These findings deepen our understanding of the immune dynamics following mRNA vaccination and offer valuable insights for designing next-generation vaccines. This study was registered at the Chinese Clinical Trial Registry (ChiCTR2100049104).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.